Triage of women with low-grade cervical lesions--HPV mRNA testing versus repeat cytology

Sveinung Wergeland Sørbye, Marc Arbyn, Silje Fismen, Tore Jarl Gutteberg, Elin Synnøve Mortensen, Sveinung Wergeland Sørbye, Marc Arbyn, Silje Fismen, Tore Jarl Gutteberg, Elin Synnøve Mortensen

Abstract

Background: In Norway, women with low-grade squamous intraepithelial lesions (LSIL) are followed up after six months in order to decide whether they should undergo further follow-up or be referred back to the screening interval of three years. A high specificity and positive predictive value (PPV) of the triage test is important to avoid unnecessary diagnostic and therapeutic procedures.

Materials and methods: At the University Hospital of North Norway, repeat cytology and the HPV mRNA test PreTect HPV-Proofer, detecting E6/E7 mRNA from HPV types 16, 18, 31, 33 and 45, are used in triage of women with ASC-US and LSIL. In this study, women with LSIL cytology in the period 2005-2008 were included (n = 522). Two triage methods were evaluated in two separate groups: repeat cytology only (n = 225) and HPV mRNA testing in addition to repeat cytology (n = 297). Histologically confirmed cervical intraepithelial neoplasia of grade 2 or worse (CIN2+) was used as the study endpoint.

Results: Of 522 women with LSIL, 207 had biopsies and 125 of them had CIN2+. The sensitivity and specificity of repeat cytology (ASC-US or worse) were 85.7% (95% confidence interval (CI): 72.1, 92.2) and 54.4 % (95% CI: 46.9, 61.9), respectively. The sensitivity and specificity of the HPV mRNA test were 94.2% (95% CI: 88.7, 99.7) and 86.0% (95% CI: 81.5, 90.5), respectively. The PPV of repeat cytology was 38.4% (95% CI: 29.9, 46.9) compared to 67.0% (95% CI: 57.7, 76.4) of the HPV mRNA test.

Conclusion: HPV mRNA testing was more sensitive and specific than repeat cytology in triage of women with LSIL cytology. In addition, the HPV mRNA test showed higher PPV. These data indicate that the HPV mRNA test is a better triage test for women with LSIL than repeat cytology.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Flow chart showing the two…
Figure 1. Flow chart showing the two study populations.

References

    1. ACOG. ACOG Practice Bulletin No. 99. Management of abnormal cervical cytology and histology. Obstet Gynecol. 2008;112:1419–1444.
    1. Jordan J, Arbyn M, Martin-Hirsch P, Schenck U, Baldauf JJ, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology. 2008;19:342–354.
    1. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, et al. Virologic versus cytologic triage of women with equivocal Pap-smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst. 2004;96:280–293.
    1. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol. 2005;99(3) Suppl 1:S7–11.
    1. Boardman LA, Kennedy CM. Management of atypical squamous cells, low-grade squamous intraepithelial lesions, and cervical intraepithelial neoplasia 1. Obstet Gynecol Clin North Am. 2008;35:599–614.
    1. Wright TC, Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinsonet EJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197:346–355.
    1. Ronco G, Cuzick J, Segnan N, Brezzi S, Carozzi F, et al. HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer. 2007;43:476–480.
    1. Thrall MJ, Smith DA, Mody DR. Women >or = 30 years of age with low grade squamous intraepithelial lesion (LSIL) have low positivity rates when cotested for high-risk human Papillomavirus: should we reconsider HPV triage for LSIL in older women? Diagn Cytopathol. 2010;38:407–412.
    1. Arbyn M, Martin-Hirsch P, Buntinx F, Van Ranst M, Paraskevaidis E, et al. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med. 2009;13:648–659.
    1. Arbyn M, Martin-Hirsch P, Buntinx F. Immediate colposcopy referral in women with low-grade abnormal results on cervical cytology detects more CIN2 or worse lesions than cytological surveillance in primary care, but might lead to overtreatment. Evid Based Med. 2010;15:13–14.
    1. Sorbye SW, Fismen S, Gutteberg T, Mortensen ES. Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing. PLoS One. 2010;5(9):e12724.
    1. Richart RM. Cervical intraepithelial neoplasia. Pathol Annu. 1973;8:301–328.
    1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342–350.
    1. Cattani P, Zannoni GF, Ricci C, D'Onghia S, Trivellizzi IN, et al. Clinical performance of human Papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J Clin Microbiol. 2009;47:3895–3901.
    1. Molden T, Kraus I, Karlsen F, Skomedal H, Nygard JF et al. Comparison of human Papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev. 2005;14:367–372.
    1. Molden T, Nygard JF, Kraus I, Karlsen F, Nygard M, et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap-smear. Int J Cancer. 2005;114:973–976.
    1. Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev. 2008;17:3033–3042.
    1. Trope A, Sjoborg K, Eskild A, Cuschieri K, Eriksen T, et al. Performance of human Papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia. J Clin Microbiol. 2009;47:2458–2464.
    1. Bjerre P, Silfverdal L, Dillner L, Hagmar B, Edvardsson H, et al. A randomized trial of basing treatment on human Papillomavirus and/or cytology results in low-grade cervical lesion triage. Am J Obstet Gynecol. 2008;199:24–27.
    1. Brismar-Wendel S, Froberg M, Hjerpe A, Andersson S, Johansson B. Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions. Br J Cancer. 2009;101:511–517.
    1. Dillner L, Kemetli L, Elfgren K, Bogdanovic G, Andersson P, et al. Randomized healthservices study of human Papillomavirus-based management of low-grade cytological abnormalities. Int J Cancer. 2011;129:151–159.
    1. The ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. AJOG. 2003;188:1383–1392.
    1. The ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. AJOG. 2003;188:1393–1400.
    1. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, et al. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;(24) Suppl 3 S3-78-S3/89.
    1. Sorbye SW, Fismen S, Gutteberg TJ, Mortensen ES. HPV mRNA test in women with minor cervical lesions: experience of the University Hospital of North Norway. J Virol Methods. 2010;169:219–222.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren